2019

DanPET AB was represented by CEO Dan Peters at French-Swedish Life Science Days 2019 in Paris, 1-2 October, who delivered a pitch about improved imaging of vulnerable plaque by the novel PET ligand 18F-NS14490

https://french-swedish-life-science-day-2019.b2match.io/

DanPET AB is participating in NLS 10-12 September (Nordic Life Science Days) 2019 MalmöMässan – Mässgatan 6, 215 32 Malmö – Sweden https://www.nlsdays.com/

 

Henriette Filholm Kihl defended her PhD thesis the 2nd of April 2019 at the Graduate School of Health and Medical Sciences in Copenhagen and consequently the PhD degree was awarded:

“Towards Light Controlled Pharmacological Tools Targeting Inner Retinal Neurons - Design, Synthesis, Photochemical and Pharmacological Evaluation”

The assessment committee consisted of: Tommy Nørskov Johansen, Associate Professor (Chairperson) Dr Dan Peters and Dr. Ulrik Svane Sørensen

Radiosynthesis of the norepinephrine transporter tracer [18F]NS12137 via copper‐mediated 18F‐labelling was published in Journal of Radiolabeled Compounds and Pharmaceuticals. https://onlinelibrary.wiley.com/doi/full/10.1002/jlcr.3717 

Dan Peters, CEO of DanPET AB, commented: Very impressive paper showing that this procedure can be  can be adapted to GMP production.

 

DanPET AB is participating at Swiss Nordic Bio 2019 7 February 2019 / Zürich, Switzerland

https://swissnordicbio.com/

[18F]NS12137 was synthesized in good yield and high molar activity and demonstrated the characteristics of a good radiotracer, such as good brain penetration, fast washout, and high specific binding to NET.

http://www.thno.org/v09p0011.htm

Dan Peters, CEO of DanPET AB, commented: - The successful studies presented and blue-stamped in Theranostics is paving the way for the upcoming first-in-human studies.

DanPET •Diversity •ambition •next generation •Partnership •Empowerment •Trust 

2018 

Edinburgh University together with DanPET AB presents at the WMIC World Molecular Imaging Congress 2018 September 12 – 15, 2018, Washington State Convention Center

TITLE: Alpha7 nicotinic acetylcholine receptor imaging with 18F-NS14490 in the context of angiogenesis

Angiogenesis plays a major role in a number of cardiovascular pathologies, including the development of vulnerable plaque and ventricular remodeling following myocardial infarction.

This study suggests that NS14490 holds potential as a marker of the onset of angiogenesis through the upregulation of alpha7. 

https://www.xcdsystem.com/wmis/program/ro23cRI/index.cfm?pgid=297&sid=4733

Dan Peters, CEO of DanPET AB, commented: - It is a true honor to communicate data that supports 18F-NS14490 as a marker of angiogenesis. DanPET AB holds IPR for 18F-NS14490.

Dr Adriana Tavares – our collaboration partner on 18F-NS14490 - Research in a nutshell

https://media.ed.ac.uk/media/1_8tlzvqfu

Hear from Dr Adriana Tavares, head of the preclinical PET-CT facility, as she discusses her research into developing new imaging probes - radiotracers - for PET imaging.

755.10 - Preclinical characterization of AN317, a novel subtype selective nicotinic α6 receptor agonist with potential in Parkinson’s disease was presented at SFN, San Diego, 2018

https://ativsoftware.com/appinfo.php?page=Inthtml&project=SFN18&server=eventpilot.us&id=6145

 

283.18 - Properties of novel alpha7 nicotinic acetylcholine receptor ligands for predicting performance as PET tracers was presented at SFN, San Diego, 2018

https://ativsoftware.com/appinfo.php?page=Inthtml&project=SFN18&server=eventpilot.us&id=4305

The Journal of Sexual Medicine, July 2018, Volume 15, Issue 7, Supplement 3, S136

S. Comerma-Steffensen, A. Kun, G. Munro, D. Peters, U. Simonsen

029 A novel dopamine reuptake inhibitor, IPED2015 induces spontaneous erections through activation of dopamine receptors in rats https://www.jsm.jsexmed.org/article/S1743-6095(18)30305-9/pdf

Dan Peters, CEO of DanPET AB, commented: - These important IPED2015-data will likely translate to patients with a great unmet need in the future http://www.initiatorpharma.com/

Sophie Valembois defended her PhD thesis the 4th of July 2018 at the Graduate School of Health and Medical Sciences in Copenhagen and consequently the PhD degree was awarded:

“Transporter-mediated drug delivery for retinal GABAAR ligands, a novel therapeutic approach in retinal degenerative disorders”

The assessment committee consisted of: Associate Professor Birger Brodin,  Dr Dan Peters and Professor Arto Urtti

The world-acknowledged research group of Professor Peter Brust and DanPET AB recently published:

Synthesis and radiofluorination of novel fluoren-9-one based derivatives for the imaging of α7 nicotinic acetylcholine receptor with PET - Bioorg Med Chem Lett. 2018 May 15; 28(9):1471-1475.

https://www.ncbi.nlm.nih.gov/pubmed/29628323

Dan Peters, CEO of DanPET AB, commented: We are very positive about our fruitful collaboration with HZDR in Leipzig in this challenging research field with great relevance to diseases inside and outside the CNS.

The publication in Glia (2018, 66, 1611–1624): In vivo imaging of alpha7 nicotinic receptors as a novel method to monitor neuro-inflammation after cerebral ischemia confirms the usefulness of 11C-NS14492 in relation to microglia and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/29528142

Dan Peters, CEO of DanPET AB, commented: Great science with tools relating to 11C-NS14492 delivered by Novandi Chemistry AB, Sweden) http://www.novandi.se/project/ns14492-3h/

NEW TREATMENT FOR ERECTION-PROBLEMS (story by Mette Louise Ohana 21.08.2018)

http://newsroom.au.dk/nyheder/vis/artikel/biomedicinske-forskere-paa-vej-med-ny-behandling-af-rejsningsproblemer/

DanPET AB is participating at Swiss Nordic Bio 2018 8 February 2018 / Zürich, Switzerland http://swissnordicbio.com/

Dan Peters, CEO of DanPET presented: 18F-14490 a new PET imaging for vulnerable plaque in atherosclerosis based on angiogenesis and inflammation http://www.swissnordicbio.com/index.php/agenda-2018?_ga=2.40513697.2019715482.1516351578-11863012.1516351578

Turku University, Åbo Akademi University, Turku PET center together with DanPET AB, have synthesized [18F]NS12137 as a radiotracer for positron emission tomography (PET) and have demonstrated that it is highly specific for in vivo detection of NET-rich regions of rat brain tissue.

http://www.sciencedirect.com/science/article/pii/S0969805117301725

Dan Peters, CEO of DanPET AB, commented: We are very happy to move this important asset forward. Several psychiatric and neurodegenerative diseases are associated with malfunction of brain norepinephrine transporter (NET). Current clinical evaluations of NET function are limited by the lack of sufficiently sensitive methods of detection. The successful radiosynthesis and preclinical evaluation warrant further development of this radiotracer. We are developing a nucleophilic radiosynthesis for the radiotracer with Good Manufacturing Practice (GMP) production and subsequent clinical use in mind.

DanPET •Diversity •ambition •next generation •Partnership •Empowerment •Trust 

2017

HIH (National Institutes of Health) BUYS 3H-NS14492 FROM NOVANDI CHEMISTRY AB

https://govtribe.com/contract/award/hhsn271201700687p

Dan Peters, CEO of DanPET AB, commented:  - We are very proud that DanPET AB and NOVANDI CHEMISTRY AB can support one of the most important institutions of world - such as NIH - with scientific tools.

Catalytic Grants 2017 - Code:CGA/17/14

Lead PI Dr. Adriana Tavares, Edinburgh University was rewarded by the CSO (Chief Science Office).

Title:  Positron emission tomography of human vascular and myocardial angiogenesis with 18F-NS-14490

http://www.cso.scot.nhs.uk/outputs/cso-funded-research/catalytic-grants-2017/

Anne Stæhr Haugaard defended her PhD thesis the 15th of September 2017 at the Graduate School of Health and Medical Sciences in Copenhagen and consequently the PhD degree was awarded:

“Modulation of GABA Mediated Tonic Inhibition - Targeting the Extrasynaptic GABAA Receptors and Transporters”

The assessment committee consisted of: Dr Dan Peters, Professor Mary Collins and Professor Jesper Langgaard Kristensen

Dr. Winnie Deuther-Conrad, HZDR together with DanPET AB presented PET imaging of α7 nicotinic acetylcholine receptors in a heterotopic xenograft model of brain cancer at ISRS 2017, May 14-19 in Dresden (22nd International Symposium on Radiopharmaceutical Sciences). Results indicated suitability of [18F]NS10743 for molecular characterization of glioblastoma.

Dan Peters, CEO of DanPET AB, commented: Great work by HZDR in an area with huge unmet patient need - [18F]NS10743 is a valuable research tool. Novandi Chemistry AB is providing both precursor and reference to [18F]NS10743 in addition to [3H]NS10743.

Initiator Pharma A/S listing on AktieTorget has been oversubscribed by 215%.  The first day for trading on AktieTorget is expected to occur March 16, 2017.  http://www.initiatorpharma.com/

DanPET AB was represented by CEO Dan Peters at the third edition of BIAT - Innovation and High Technology Lab http://innovationlab2017.ice.it/home  which took place in Catania, Italy in March 3rd - 4th 2017.

DanPET AB was represented SWISS NORDIC BIO 8 February 2017 at SIX Swiss Exchange in Zurich. CONNECTING HEALTHCARE, INNOVATIONS, INVESTORS AND INDUSTRY. Dan Peters presented the pitch: Diagnosis and treatment of vulnerable plaque.   http://www.swissnordicbio.com/

 

DanPET •Diversity •ambition •next generation •Partnership •Empowerment •Trust 

2016

ACKNOWLEDGEMENT OF SME-VERIFIERINGSMEDEL TO DANPET AB

DanPET AB has received funding for commercial verification of 18F-NS14490 one of its product candidates from SWElife.

Dan Peters, CEO of DanPET AB, commented:  -The support from Karolinska Institutet Innovations AB, professionally handled by Patrik Blomquist is very helpful, paving the way for new technology within a field with a huge unmet need in order to decrease the number of strokes and related deaths in the future.

DanPET AB was represented at the 3rd edition of Meet in Italy for Life Sciences (MIT4LS2016), the international event designed to boost business, partnering and networking opportunities in the life sciences sector by invitation of the Italian Trade Agency. Read more

Dan Peters, CEO of DanPET AB, commented:  A very much appreciated event with opportunity to increase your international relationship network, give you the possibility to meet many potential business partners in a short time and allow you to showcase your organization.

 

DANPET AB INVOLVED IN FOUNDING OF INITATOR PHARMA.

Initiator Pharma is a newly established biotech company based in Aarhus, Denmark. The company’s lead compound IPED2015 represents a novel treatment paradigm for the treatment of Erectile Dysfunction (ED) and may improve the quality of life for the growing number for patients (and their partners) that do not respond or cannot be treated with the current marketed medication. Read more

Dan Peters, CEO of DanPET AB, commented:  The major unmet medical need constitutes a unique opportunity for launching IPED2015 targeting patients, which do not respond to PDE5i drugs.

Read more Initiator Pharma info starts at 12 minutes.

Tos-Nos-Mos: Synthesis of different aryl sulfonate precursors for the radiosynthesis of the alpha7 nicotinic acetylcholine receptor radioligand [(18)F]NS14490. Appl Radiat Isot. 2016 Aug;114:57-62.

Read more

Dan Peters, CEO of DanPET AB, commented:  -These useful results further illustrates the practical potential to develop 18F-NS14490 further as a diagnostic method to vulnerable plaque and as a companion diagnostic along with NS14490.

BrainGain Sweden is a collaborative effort compiled by a host of national stakeholders from industry, academia and other organizations - Read more from mission to action plan about innovation, funding, network and competence http://www.braingainsweden.org/

Dan Peters, CEO of DanPET AB, commented: - we are honored to contribute as a partner to this great work

 

A locus coeruleus biomarker of cognitive reserve in healthy aging Neurobiology of Aging 37 (2016) 117-126.  Read more

Dan Peters, CEO of DanPET AB, commented:  These findings support the idea that, by augmenting locus coeruleus NE system function, the same intellectually engaging experiences that help enrich one’s life might also protect cognitive health in later adulthood.  DanPET AB develops two of the most promising NET-PET ligands, namely 11C-NS8880 and 18F-NS12137.

The role of Locus Coeruleus and norepinephrine is essential for maintaining cognitive function and the aging brain. Mara Mather and Carolyn W. Harley Trends in Cognitive Sciences Volume 20, Issue 3, p214–226, March 2016. Read more

Dan Peters, CEO of DanPET AB, commented:  -This important publication highlights the importance of NE and potential for NET PET ligands in the future use as Alzheimer´s diagnosis. Read more

 

DanPET AB was represented by CEO Dan Peters at the second edition of BIAT - Innovation and High Technology Lab (Read more) which took place in Bari (Apulia Region) in February 11th - 12th 2016.

 

[(11)C]NS9531, [(11)C]NS9762 and [(11)C]NS6417, specific SERT tracers: pre-clinical evaluation in pigs and optimization of synthesis conditions using [(11)C]methyl triflate. Read more

Dan Peters, CEO of DanPET AB, commented:  -This positive results opens up for investigating the corresponding 18F ligands with a more adequate half-life. [(11)C]DASB is currently the most frequently used highly selective radiotracer for visualization and quantification of central SERT. Its use, however, is hampered by the short half-life of (11)C.

DanPET •Diversity •ambition •next generation •Partnership •Empowerment •Trust 

 

2015

A Promising PET Tracer for Imaging of alpha7 Nicotinic Acetylcholine Receptors in the Brain: Design, Synthesis, and in Vivo Evaluation of a Dibenzothiophene-Based Radioligand. Read more The PET radioligand ([18F]DBT-10) has high potential to provide clinically relevant information about the expression and availability of alpha7 nAChR in the brain.

 

DanPET AB  was represented by CEO Dan Peters  Drug Discovery Innovation Programme (DDIP) 25-26 November , 2015 in Munich. Read more

MULTITASKING

https://www.youtube.com/watch?v=5jKaYqXaQ6U

Samarbejdspartner Professor Jens Mikkelsen, NRU,  forklarer, hvad der sker, når hjernen skal lære, og hvordan multitasking i undervisningen kan få det hele til at koge over.

 

Radiosynthesis and in vitro validation of (3)H-NS14492 as a novel high affinity alpha7 nicotinic receptor radioligand. Read more

Dan Peters, CEO of DanPET AB, commented: -The success of 3H-NS14492 became possible thanks to support from CCJobs, the successful collaboration with NRU, COGNITO and partnering with Novandi AB Read more

In addition – the precursor and the reference (cold ligand) corresponding to the PET-ligand 11C-NS14492 are also offered by Novandi. Read more

 

Engineered α4β2 nicotinic acetylcholine receptors as models for measuring agonist binding and effect at the orthosteric  low-affinity α4-α4 interface. Read more

Dan Peters, CEO of DanPET AB, commented:  -Large differences in activities at a4-b2 vs. a4-a4 interfaces were observed for structurally related agonists underscoring the need for establishing all binding parameters of compounds at a4b2 receptors. Important tool compounds as NS3531, NS3573 and 3H-NS3573 are available from Novandi Chemistry AB.

DanPET •Diversity •ambition •next generation •Partnership •Empowerment •Trust 

 

2014

A high-yield automated radiosynthesis of the alpha-7 nicotinic receptor radioligand [18F]NS10743. http://www.ncbi.nlm.nih.gov/pubmed/25464181

http://www.ncbi.nlm.nih.gov/pubmed/21290632

http://www.ncbi.nlm.nih.gov/pubmed/19137292

http://www.ncbi.nlm.nih.gov/pubmed/21484373

The great story about our partner HZDR Leipzig and how antimatter helps to image brain diseases

The scientists at the HZDR Research Site Leipzig for Interdisciplinary Isotope Research present their aspects of their current research with this short clip. Prof. Dr. Peter Brust provides insight into their work and explains how antimatter helps to image brain diseases like Alzheimer's.

https://www.youtube.com/watch?v=51oiGtmOvFI

Congratulations to Gitte Moos Knudsen Carlsbergfondets forskningspris 2014

https://alchetron.com/Gitte-Moos-Knudsen

 

Imaging of α7 nicotinic acetylcholine receptors in brain and cerebral vasculature of juvenile pigs with [(18)F]NS14490. http://link.springer.com/article/10.1186%2Fs13550-014-0043-5

http://jnumedmtg.snmjournals.org/cgi/content/short/55/1_MeetingAbstracts/1695 https://openi.nlm.nih.gov/detailedresult.php?img=4129469_s13550-014-0043-5-4&req=4

DanPeters, CEO of DanPET AB, commented:  -[18F]NS14490 is not only comparable to other preclinically investigated PET radiotracers for imaging of alpha7 nAChR in brain but could also be a potential PET radiotracer for imaging of α7 nAChR in vulnerable plaques of diseased vessels. Precursor to 18F-NS14490 and cold reference NS14490 are available from Novandi AB.

 

[11C]NS8880 - a promising PET radiotracer targeting the norepinephrine transporter. http://www.ncbi.nlm.nih.gov/pubmed/25127515

DanPeters, CEO of DanPET AB, commented: -High quality NET PET ligands are missing – 11C-NS8880 is an important step in the right direction. Noradrenaline’s neuroprotective effects both in vivo and in vitro, and its key role in mediating the neuroprotective effects of environmental enrichment on the brain, make noradrenaline’s key role in mediating cognitive reserve - by disease compensation and disease modification. http://www.ncbi.nlm.nih.gov/pubmed/22743090

 

Biophysical and pharmacological characterization of alpha6-containing nicotinic acetylcholine receptors expressed in HEK293 cells. http://www.ncbi.nlm.nih.gov/pubmed/24157862

DanPeters, CEO of DanPET AB, commented: -This alpha6 -receptor chimera α6/α3β2β3(V9'S) provided an important tool for drug discovery efforts, such as the alpha6 agonist NS10712. Accumulating literature points to a significant and possibly predominant role for alpha6 -nAChRs in modulating dopaminergic function in the mesolimbic and nigrostriatal dopaminergic pathways and  may represent novel therapeutic targets for addiction and for the treatment of movement disorders such as Parkinson's disease. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3264546/

 

DanPET-crowdfunding -Novel tools against Alzheimer's disease (recommended reading – the updates): http://igg.me/p/620882/x/5770226

 DanPeters, CEO of DanPET AB, commented: Crowdfunding was very rewarding in terms of stablishing personal contacts and spreading our mission.

 

BioJapan2014 Exhibitor's Presentation Tokyo Oct. 15(Wed.), 2014-10:55-11:25  http://www.ics-expo.jp/biojapan/2014seminar/exhibitor/43.html

DanPET •Diversity •ambition •next generation •Partnership •Empowerment •Trust 

 

2013

DanPET Sign Pharma Service Deal With Novandi

On October 30, 2013 DanPET announced that 11C-NS14492 was sold exclusively by Novandi Chemistry and was available off the shelf. As such they could be delivered with short notice. They were delivered by courier service and were accompanied with a certificate of analysis.

https://www.cmocro.com/news_detail/DanPET+Sign+Pharma+Service+Deal+With+Novandi/210609/index.html

Two distinct allosteric binding sites at α4β2 nicotinic acetylcholine receptors revealed by NS206 and NS9283 give unique insights to binding activity-associated linkage at Cys-loop receptors. http://www.ncbi.nlm.nih.gov/pubmed/24169695

 

Structural analysis of the positive AMPA receptor modulators CX516 and Me-CX516 in complex with the GluA2 ligand-binding domain.  http://www.ncbi.nlm.nih.gov/pubmed/23999288

 

A combined alpha7 nicotinic acetylcholine receptor agonist and monoamine reuptake inhibitor, NS9775, represents a novel profile with potential benefits in emotional and cognitive disturbances. http://www.ncbi.nlm.nih.gov/pubmed/23748055

DanPeters, CEO of DanPET AB, commented:  -NS9775 combine to important concepts against AD: alpha7 agonism http://www.alzforum.org/therapeutics/encenicline  and stimulation mediated by norepinephrine, by the concept of cognitive reserve. http://www.ncbi.nlm.nih.gov/pubmed/22743090

 

Radiosynthesis and first evaluation in mice of [(18)F]NS14490 for molecular imaging of α7 nicotinic acetylcholine receptors. http://www.ncbi.nlm.nih.gov/pubmed/23507153

 

Molecular determinants of subtype-selective efficacies of cytisine and the novel compound NS3861 at heteromeric nicotinic acetylcholine receptors.  http://www.ncbi.nlm.nih.gov/pubmed/23229547

DanPeters, CEO of DanPET AB, commented:  3H-NS3861 is a new tool for the future investigations in the field of alpha3 nicotinic compounds. http://onlinelibrary.wiley.com/doi/10.1111/bph.12741/full

 

New α7 nicotinic acetylcholine receptor radioligands available from Novandi Chemistry: http://www.novandi.se/new-%ce%b17-nicotinic-acetylcholine-receptor-radioligands-available-from-novandi-chemistry/

 

DanPET AB was awarded by Creating Competitive Jobs (CCJobs).  CCJobs is an Interreg project between Swedish and Danish universities and business organizations. http://ccjobs.se/danpet/ http://8till5.se/2015/01/27/samarbete-mellan-foretag-och-universitet-gav-nya-jobb-och-okad-forsaljning/

 

Synthesis of 10-methyl-8,10-diazabicyclo[4.3.1]decane as a new building block for nicotinic modulators http://quod.lib.umich.edu/cgi/p/pod/dod-idx/synthesis-of-10-methyl-810-diazabicyclo431decane-as-a-new.pdf?c=ark;idno=5550190.p008.202

 

Preparation of the C-11 labelled SERT tracers NS9531, NS9762 and NS6417 on a GE FX-C Pro module using C-11 methyl triflate. http://findresearcher.sdu.dk/portal/files/77976989/JLCR_56_S102.pdf

DanPET •Diversity •ambition •next generation •Partnership •Empowerment •Trust 

 

2012

Development of radioligands for the imaging of alpha7 nicotinic acetylcholine receptors with positron emission tomography. http://www.ncbi.nlm.nih.gov/pubmed/22300025

 

Projekt finansierat av VINNOVA: Utveckling av effektiva imaging hjälpmedel för diagnos, monitorering och behandling av mentala sjukdomar: http://www.vinnova.se/sv/Resultat/Projekt/Effekta/2011-00659/Utvekling-av-effektiva-imaging-hjalpmedel-for-diagnos--monitorering-och-behandling-av-mentala-sjukdommar/

 

DanPET Diversity •ambition •next generation •Partnership •Empowerment •Trust 

 

News